Immunotherapy Today

Immunotherapy News From Around The World

Updates in Immunotherapy for Advanced Thoracic Malignancies – OncLive

Posted by btwatson on October 26, 2020 7:38 pm
Tags:
Categories: Crispr Articles

Source: Updates in Immunotherapy for Advanced Thoracic Malignancies – OncLive

Updates in Immunotherapy for Advanced Thoracic Malignancies | OncLive

OncLive SOSS

October 26, 2020

Suresh S. Ramalingam, MD, Winship Cancer Institute , Firas Badin, MD, Baptist Health , Christine Bestvina, MD, University of Chicago , Martin Dietrich, MD, PhD, University of Central Florida , Stephen Liu, MD, Georgetown University School of Medicine


Published at Sun, 25 Oct 2020 07:00:00 +0000

< Immunotherapy Today home

Immunotherapy News

  • Combining KRAS Inhibition With Immunotherapy in NSCLC - Targeted Oncology
    April 18, 2026
  • Why RemeGen (SEHK:9995) Is Up 13.1% After First HER2 ADC–Immunotherapy Approval in China - simplywall.st
    April 18, 2026
  • Dr. Chokshi Reflects on Presentation Addressing Immune Checkpoint Inhibitor Toxicity Management - Cancer Nursing Today
    April 17, 2026
  • Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting - PR Newswire
    April 17, 2026
  • Wungki Park: POLAR Study Provides Rationale for Precision Immunotherapy in Pancreatic Cancer - Oncodaily
    April 17, 2026
  • Report: Merck’s blockbuster cancer drug topped $200,000 a year under Trump - International Consortium of Investigative Journalists - ICIJ
    April 17, 2026
  • IRAKLIA Trial Validates Subcutaneous Isatuximab in Multiple Myeloma - Targeted Oncology
    April 17, 2026
  • Study Identifies Why Multiple Myeloma May Return After Immunotherapy - Cure Today
    April 17, 2026
  • Darlifarnib Plus Cabozantinib Active in ccRCC After Prior Cabozantinib - Targeted Oncology
    April 17, 2026
  • Genomic Insights: How BRCA2 Inherited Variants Drive Drug Resistance - Targeted Oncology
    April 17, 2026

Immunotherapy News from China

  • UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo …
  • …Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to…
  • UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo …
  • …in Combination With Anti-PD-L1 Cancer Immunotherapy and …
  • …Dosed in First-in-Human Clinical Study of Immunotherapy …
  • JITC tumor and cancer immunotherapy papers collection
    JITC tumor and cancer immunotherapy papers collection
  • Welcome to the submission|Journal for ImmunoTherapy of Cancer
  • Immunotherapy shows promise for advanced lymphoma: study
  • …from the Monotherapy Arm at the Phacilitate Immunotherapy …
  • Allergy Immunotherapy Market to exceed US$ 3.33 Bn by 2025 …
  • Load more [+]

Copyright 2018 ImmunoTherapyToday.com